2. Search Result
Search Result
Results for "

MMPs

" in MedChemExpress (MCE) Product Catalog:

297

Inhibitors & Agonists

2

Screening Libraries

8

Fluorescent Dye

5

Biochemical Assay Reagents

44

Peptides

1

Inhibitory Antibodies

40

Natural
Products

7

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153563
    MMP-7-IN-2

    		MMP Others
    MMP-7-IN-2 (compound 16) is a selective inhibitor of MMP7 with an IC50 value of 16 nM .
    <em>MMP</em>-7-IN-2
  • HY-P2179
    MMP-1/MMP-9 Substrate, Fluorogenic

    		Fluorescent Dye MMP Others
    MMP-1/MMP-9 Substrate, Fluorogenic is a fluorogenic substrate for MMP-1 and MMP-9 .Ex/Em = 340/440 nm
    <em>MMP</em>-1/<em>MMP</em>-9 Substrate, Fluorogenic
  • HY-110046
    CL-82198 hydrochloride

    		MMP Others
    CL-82198 hydrochloride is a selective inhibitor of MMP-13. CL-82198 hydrochloride binds to the entire S1’ pocket of MMP-13, which is the basis of its selectivity against MMP-1, MMP-9, and TACE .
    CL-82198 hydrochloride
  • HY-119423
    MMP Inhibitor II

    		MMP Cancer
    MMP Inhibitor II (compound 4e) is a potent, reversible pan-MMP inhibitor with IC50 values of 24 nM, 18.4 nM, 30 nM, and 2.7 nM for MMP-1,MMP-3, MMP-7, and MMP-9, respectively .
    <em>MMP</em> Inhibitor II
  • HY-P2166
    MMP3 inhibitor 3

    		MMP Cancer
    MMP3 inhibitor 3 is an inhibitor of MMP3. MMP3 inhibitor 3 can used to study breast cancer .
    <em>MMP</em>3 inhibitor 3
  • HY-147745
    MMP2-IN-2

    		MMP Cancer
    MMP2-IN-2 (compound 42) is a potent and selective MMP-2 (matrix metalloproteinases) inhibitor, with an IC50 of 4.2 μM. MMP2-IN-2 also shows inhibitory activity against MMP-13, MMP-9 and MMP-8, with IC50 values of 12, 23.3, and 25 μM, respectively .
    <em>MMP</em>2-IN-2
  • HY-161284
    MMP-9/10-IN-1

    		MMP Cancer
    MMP-9/10-IN-1 (Compound 6b) is a potent dual MMP-9/10 Inhibotor with IC50s of 0.076 and 0.139 μM against NSCLC and A549 cells, respectively. MMP-9/10-IN-1 has anti-invasive and anti-angiogenic activities when in combination with Sorafenib (HY-10201) .
    <em>MMP</em>-9/10-IN-1
  • HY-156247
    IVMT-Rx-3

    		NF-κB MMP Cancer
    IVMT-Rx-3 is a inhibitor of SDCBP targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression. IVMT-Rx-3 inhibits Melanoma Metastasis [1]
    IVMT-Rx-3
  • HY-14240
    PG 116800

    PG 530742; PGE 530742; PGE 7113313

    		 MMP Inflammation/Immunology
    PG 116800 (PG 530742) is an orally avtive MMP inhibitor. PG 116800 has high affinity for MMP-2, -3, -8, -9, -13, and -14, while having substantially lower affinity for MMP-1 and -7. PG 116800 can be used for knee osteoarthritis research .
    PG 116800
  • HY-107428
    PD-166793

    		MMP Cardiovascular Disease
    PD-166793 is a potent, selective, orally active and wide‐broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC50=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC50=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure .
    PD-166793
  • HY-156430
    MMP-7-IN-3

    		MMP Cancer
    MMP-7-IN-3 is a potent and selective inhibitor of MMP-7. MMP-7-IN-3 suppresses kidney fibrosis progression in a mouse model with unilateral ureteral obstruction .
    <em>MMP</em>-7-IN-3
  • HY-N1981
    Triolein

    		MMP Endogenous Metabolite Inflammation/Immunology
    Triolein is a symmetric triacylglycerol that reduces upregulation of MMP-1 and has strong antioxidant and anti-inflammatory activities .
    Triolein
  • HY-P3474
    Mca-Pro-Leu-Gly-Leu-Dap-Ala-Arg-NH2

    		MMP Cancer
    Mca-Pro-Leu-Gly-Leu-Dap-Ala-Arg-NH2 is a fluorescent peptide MMP substrate .
    Mca-Pro-Leu-Gly-Leu-Dap-Ala-Arg-NH2
  • HY-P3474A
    Mca-Pro-Leu-Gly-Leu-Dap-Ala-Arg-NH2 TFA

    		MMP Cancer
    Mca-Pro-Leu-Gly-Leu-Dap-Ala-Arg-NH2 (TFA) is a fluorescent peptide MMP substrate .
    Mca-Pro-Leu-Gly-Leu-Dap-Ala-Arg-NH2 TFA
  • HY-146754
    MMP2-IN-1

    		MMP Apoptosis Cancer
    MMP2-IN-1 is a moderate potenet MMP2 inhibitor with IC50 of 6.8 µM. MMP2-IN-1 exhibits remarkable antiproliferative activity in certain cancer cells by arresting the cell cycle and inducing apoptosis .
    <em>MMP</em>2-IN-1
  • HY-108672
    NF157

    		P2Y Receptor Inflammation/Immunology
    NF157 is a highly selective nanomolar P2Y11 antagonist with a pKi of 7.35. The IC50s are 463 nM, 1811 µM, 170 µM for P2Y11 (Ki=44.3 nM), P2Y1 (Ki=187 µM), P2Y2 (Ki=28.9 µM), respectively . NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA) .
    NF157
  • HY-P4931
    Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2

    Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2

    		 MMP Cancer
    Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 (FS-6) is a fluorescent peptide that is a quenched MMP peptide substrate. Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 can be used for real-time quantification of MMP enzymatic activity. Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 is an elongated peptide of MMP substrate (FS-1) and is active against collagenases (MMP-1, MMP-8, MMP-13 ) and MT1-MMP with higher specificity constants than FS-1 . (Ex/Em=325 nm/400 nm)
    Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2
  • HY-155964
    Anticancer agent 153

    		Apoptosis Cancer
    Anticancer agent 153 (Compound 3) induces apoptosis by Reactive Oxygen Species generation. Anticancer agent 153 increases the loss of mitochondrial membrane potential (MMP) levels. Anticancer agent 153 inhibits cancer cell proliferation .
    Anticancer agent 153
  • HY-146006
    Tubulin/MMP-IN-1

    		Microtubule/Tubulin MMP Cancer
    Tubulin/MMP-IN-1 (compound 15g) is a potent inhibitor of tubulin and MMP. Tubulin/MMP-IN-1 has the potential for the research of cancer diseases. Tubulin/MMP-IN-1 suppresses tubulin polymerization, induces cell cycle arrest at the G2/M phase, leads to reactive oxidative stress (ROS) generation of HepG2 cells, and results in apoptosis by the mitochondrial-dependent apoptotic pathway .
    Tubulin/<em>MMP</em>-IN-1
  • HY-P2641
    Peptide 74

    		MMP Cancer
    Peptide 74 is a synthetic peptide containing the prodomain sequence of matrix metalloproteinase (MMP). Peptide 74 inhibits the activated form of the 72-kDa type IV collagenase in vitro .
    Peptide 74
  • HY-120231
    Z-VRPR-FMK

    		MALT1 Cancer
    Z-VRPR-FMK is an irreversible MALT1 protein inhibitor. Z-VRPR-FMK inhibits the growth and invasion of diffuse large B-cell lymphoma by inhibiting MALT1-induced NF-κB activation and MMP expression .
    Z-VRPR-FMK
  • HY-126956
    Porphyra 334

    		Reactive Oxygen Species MMP Inflammation/Immunology
    Porphyra 334 is an antioxidative and anti-photoaging agent. Porphyra 334 suppresses ROS production and the expression of MMPs following UVA irradiation .
    Porphyra 334
  • HY-119307
    Apratastat
    1 Publications Verification

    TMI-005

    		 MMP TNF Receptor Cancer
    Apratastat (TMI-005) is an orally active, non-selective and reversible TACE/MMPs inhibitor, can inhibit inhibit the release of TNF-α. Apratastat has the potential to overcome radiotherapy-resistance in non-small cell lung cancer (NSCLC) . Apratastat is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Apratastat
  • HY-162011
    GPR183 antagonist-2

    		EBI2/GPR183 Inflammation/Immunology
    GPR183 antagonist-2 (compound 32) is a selective GPR183 antagonist with good water solubility and excellent pharmacokinetic properties. GPR183 antagonist-2 significantly reduces paw and joint swelling and gene expression of pro-inflammatory cytokines (MCP-1, MMPs, and VEGF) in a collagen-induced arthritis (CIA) mouse model in a dose-dependent manner. GPR183 antagonist-2 can be used in the study of autoimmune diseases .
    GPR183 antagonist-2
  • HY-128026
    MMP-9/MMP-13 Inhibitor I

    		MMP Inflammation/Immunology
    MMP-9/MMP-13 Inhibitor I is a potent MMP-9 and MMP-13 inhibitor with IC50s of both 0.9 nM. MMP-9/MMP-13 Inhibitor I shows >20-folds selectivity for MMP-9/MMP-13 over other MMPs .
    <em>MMP</em>-9/<em>MMP</em>-13 Inhibitor I
  • HY-162038
    RXP03

    		MMP Others
    RXP03 is a MMPs inhibitor with the Ki of 20 nM, 2.5 nM, 10 nM, 5nM and 105 nM for MMP-2, MMP-8, MMP-9, MMP-11, MMP-14, respectively .
    RXP03
  • HY-13564
    Batimastat
    5+ Cited Publications

    BB94

    		 MMP Cancer
    Batimastat is a potent broad spectrum MMP inhibitor with IC50 of 3, 4, 4, 6, and 20 nM for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3, respectively.
    Batimastat
  • HY-13564A
    Batimastat sodium salt

    BB-94 sodium salt

    		 MMP Cancer
    Batimastat sodium salt is a potent broad spectrum MMP inhibitor with IC50 of 3, 4, 4, 6, and 20 nM for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3, respectively.
    Batimastat sodium salt
  • HY-107394
    UK 356618
    4 Publications Verification

    		 MMP Inflammation/Immunology Cancer
    UK 356618 (Compound 4j) is a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) with an IC50 of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with MMP-3 .
    UK 356618
  • HY-116399
    MMP-2/MMP-9-IN-1

    		MMP Cancer
    MMP-2/MMP-9-IN-1 is a highly selective, orally active and potent type IV collagenase (MMP-9 and MMP-2) inhibitor with IC50s of 0.24 and 0.31 μM for MMP-9 and MMP-2, respectively. MMP-2/MMP-9-IN-1 is orally active in animal models of tumor growth and metastasis. MMP-2/MMP-9-IN-1 can be used for the research of cancer .
    <em>MMP</em>-2/<em>MMP</em>-9-IN-1
  • HY-116302
    MMP-9-IN-9

    		MMP Neurological Disease Inflammation/Immunology
    MMP-9-IN-9 (compound 4f) is a slective MMP-9 inhibitor with an IC50 of 5 nM. MMP-9-IN-9 shows selective for MMP-9 over MMP-1 and MMP-13. MMP-9-IN-9 shows strong anti-inflammatory and neuroprotective effects .
    <em>MMP</em>-9-IN-9
  • HY-112160
    XL-784 free base

    		MMP Cardiovascular Disease
    XL-784 free base is a selective matrix metalloproteinases (MMP) inhibitor, with IC50s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13, respectively .
    XL-784 free base
  • HY-130076
    MMP-2 Inhibitor II

    		MMP Cancer
    MMP-2 Inhibitor II (compound 2) is a selective MMP-2 inhibitor. The Kinetic parameters for MMP inhibition are 2.4 μM (MMP-2), 45 μM (MMP-1), and 379 μM (MMP-7), respectively .
    <em>MMP</em>-2 Inhibitor II
  • HY-W011085
    CP-471474

    		MMP Inflammation/Immunology
    CP-471474 is an orally active and pan MMP inhibitor, with IC50 values of 1170 nM (MMP-1), 0.7 nM (MMP-2), 16 nM (MMP-3), 13 nM (MMP-9) and 0.9 nM (MMP-13), respectively .
    CP-471474
  • HY-19485
    XL-784
    1 Publications Verification
    XL-784 is a selective matrix metalloproteinases (MMP) inhibitor, with IC50s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1，MMP-2，MMP-3，MMP-8，MMP-9，MMP-13，respectively.
    XL-784
  • HY-107639
    UK-370106

    		MMP Inflammation/Immunology
    UK-370106 is a potent and highly selective MMP-3 (IC50 of 23 nM) and MMP-12 (IC50 of 42 nM) inhibitor with >1200-fold higher potency than MMP-1, MMP-2, MMP-9, and MMP-14, and about 100-fold than MMP-13 and MMP-8. UK-370106 potently inhibits cleavage of [ 3H]-fibronectin by MMP-3 (IC50 of 320 nM) and has little effect on keratinocyte migration in vitro .
    UK-370106
  • HY-15768
    Ilomastat
    35+ Cited Publications

    GM6001; Galardin

    		 MMP Cancer
    Ilomastat (GM6001) is a potent and broad spectrum matrix metalloprotease (MMP) inhibitor, inhibits MMPs (IC50s, 1.5 nM for MMP-1; 1.1 nM for MMP-2; 1.9 nM for MMP-3; 0.5 nM for MMP-9), with a Ki of 0.4 nM for human skin fibroblast collagenase (MMP-1).
    Ilomastat
  • HY-N1463
    Luteolin 7-O-glucuronide
    1 Publications Verification

    Luteolin 7-glucuronide
    Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively .
    Luteolin 7-O-glucuronide
  • HY-P2414
    MMP-13 Substrate

    		MMP Inflammation/Immunology
    MMP-13 Substrate is a substrate of MMP-13. MMP-13 Substrate can be used for the research of osteoarthritis (OA) .
    <em>MMP</em>-13 Substrate
  • HY-146218
    MMP-9-IN-5

    		MMP Akt Apoptosis Cancer
    MMP-9-IN-5 is a MMP-9 inhibitor (IC50: 4.49 nM) that forms hydrogen bond with MMP-9. MMP-9-IN-5 also inhibits AKT activity (IC50: 1.34 nM). MMP-9-IN-5 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-5 can be used in the research of cancers .
    <em>MMP</em>-9-IN-5
  • HY-146216
    MMP-9-IN-3

    		MMP Akt Apoptosis Cancer
    MMP-9-IN-3 is a MMP-9 inhibitor (IC50: 5.56 nM) that forms hydrogen bond with MMP-9. MMP-9-IN-3 also inhibits AKT activity (IC50: 2.11 nM). MMP-9-IN-3 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-3 can be used in the research of cancers .
    <em>MMP</em>-9-IN-3
  • HY-147746
    MMP2-IN-3

    		MMP Cancer
    MMP2-IN-3 (compound 2) is a potent MMP-2 (matrix metalloproteinases) inhibitor, with an IC50 of 31 μM. MMP2-IN-3 also shows inhibitory activity against MMP-9 and MMP-8, with IC50 values of 26.6, and 32 μM, respectively .
    <em>MMP</em>2-IN-3
  • HY-12170
    Prinomastat
    2 Publications Verification

    AG3340; KB-R9896

    		 MMP Apoptosis Cancer
    Prinomastat (AG3340) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC50s of 79, 6.3 and 5.0 nM for MMP-1, MMP-3 and MMP-9, respectively. Prinomastat inhibits MMP-2, MMP-3 and MMP-9 with Kis of 0.05 nM, 0.3 nM and 0.26 nM, respectively. Prinomastat crosses blood-brain barrier. Antitumor avtivity .
    Prinomastat
  • HY-146217
    MMP-9-IN-4

    		MMP Akt Apoptosis Cancer
    MMP-9-IN-4 is a MMP-9 inhibitor (IC50: 7.46 nM) that has H-π interactions with MMP-9. MMP-9-IN-4 also inhibits AKT activity (IC50: 8.82 nM). MMP-9-IN-4 shows cell cytotoxicity and induces cell apoptosis. MMP-9-IN-4 can be used in the research of cancers .
    <em>MMP</em>-9-IN-4
  • HY-P3098
    Mca-P-Cha-G-Nva-HA-Dap(DNP)-NH2

    		MMP Others
    Mca-P-Cha-G-Nva-HA-Dap(DNP)-NH2 is a fluorogenic substrate for matrix metalloproteinase-1 (MMP-1), MMP-3, and MMP-26. Mca-P-Cha-G-Nva-HA-Dap(DNP)-NH2 can be used to quantify MMP-1, MMP-3 and MMP-26 activity .
    Mca-P-Cha-G-Nva-HA-Dap(DNP)-NH2
  • HY-N1454
    Apigenin-7-glucuronide
    1 Publications Verification

    Apigenin 7-O-glucuronide
    Apigenin-7-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively.
    Apigenin-7-glucuronide
  • HY-P2682
    MMP-8/MMP-26 Fluorogenic substrate

    		MMP Metabolic Disease
    MMP-8/MMP-26 Fluorogenic substrate (DNP-Pro-Leu-Ala-Tyr-Trp-Ala-Arg) is a matrix metalloproteinase-8 (MMP-8) fluorogenic substrate. MMP-8/MMP-26 Fluorogenic substrate can be used for the research of atherosclerosis, pulmonary fibrosis, and sepsis .
    <em>MMP</em>-8/<em>MMP</em>-26 Fluorogenic substrate
  • HY-153913
    MMP-9-IN-7

    		MMP Inflammation/Immunology
    MMP-9-IN-7 is a potent MMP9 inhibitor with an IC50 of 0.52 μM in proMMP9/MMP3 P126 activation assay. MMP-9-IN-7 is extracted from patent WO2012162468 (example 59), and can be used for MMP9/MMP13 mediated syndrome research .
    <em>MMP</em>-9-IN-7
  • HY-135232
    MMP-9-IN-1
    5 Publications Verification

    		 MMP Cancer
    MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs .
    <em>MMP</em>-9-IN-1
  • HY-P4574
    VPLSLYSG

    		MMP Others
    VPLSLYSG is an octapeptide that can be degraded by matrix metalloproteinase-9 (MMP-9), MMP-1 and MMP-2. VPLSLYSG has potential applications in MMP substrates .
    VPLSLYSG

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: